Global Search | Novartis

Hide Filters

Showing 2804 results

Press release / Jan 03, 2018

Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer

Designation based on Phase III MONALEESA-7 results demonstrating superior efficacy of Kisqali in combination with oral endocrine therapy compared to oral endocrine therapy in pre- or perimenopausal…
Press release / Jan 09, 2018

Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**

SURPASS is the first head-to-head superiority trial versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS)[1] EXCEED is the first head-to-head superiority trial…
Ad hoc release / Jan 11, 2018

Novartis appoints Elizabeth Barrett as Oncology Head

Novartis appoints experienced pharmaceuticals industry leader with strong marketing skills to drive oncology business further Novartis appoints ad interim leader for its Global Drug Development…
Ad hoc release / Jan 11, 2018

Novartis ernennt Elizabeth Barrett zur Chefin Onkologie

Novartis ernennt eine erfahrene Pharma-Führungskraft mit starken Marketingfähigkeiten, um das Onkologiegeschäft weiter zu entwickeln Novartis ernennt ad interim Leiter für die Global Drug…
Press release / Jan 16, 2018

Novartis new data reinforces superiority of Cosentyx® versus Stelara®* in achieving skin clearance for psoriasis patients

Results from CLARITY study show Cosentyx® (secukinumab) was significantly more effective than Stelara®* (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks[1]…
Press release / Jan 16, 2018

Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA

Adalimumab is an anti-TNF medicine used to treat a range of immunological diseases[1] The comprehensive data package provided is expected to demonstrate that Sandoz proposed biosimilar adalimumab…
Press release / Aug 31, 2016

AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment

New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®. Study highlights importance of improving…
Press release / Sep 03, 2016

Novartis' Ultibro® Breezhaler® consistently more effective than Seretide®* in reducing COPD flare-ups across different patient groups

Ultibro® Breezhaler® reduced rate of all COPD exacerbations across different patient sub-groups vs Seretide® in new analyses from FLAME study Analyses show that Ultibro Breezhaler lowered…
Press release / Sep 09, 2016

New Novartis point of care Niji(TM) System may provide earlier diagnosis of severe allergic asthma and faster treatment decisions

NijiTM System, Total IgE Test delivers results rapidly, allowing for quick in-office diagnosis of IgE-mediated allergic disorders and faster treatment decisions Point of care in office…
Press release / Sep 08, 2016

Alcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experience

Heads-up design using high definition 3D screen engineered to improve surgeons posture and may reduce fatigue[1] Offers enhanced 3D visualization with high-definition resolution, image…